International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 537-543 , June 2010

Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates

  • David J. Farrell

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 319 665 3370; fax: +1 319 665 3371.
    • ,
  • Helio S. Sader

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • ,
  • Mariana Castanheira

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • ,
  • Douglas J. Biedenbach

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • ,
  • Paul R. Rhomberg

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • ,
  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • Tufts University School of Medicine, Boston, MA, USA

Received 9 December 2009 ,Accepted 25 January 2010.

References 

  1. World Health Organization. Acute respiratory infections (update September 2009). Geneva, Switzerland, WHO. http://www.who.int/vaccine_research/diseases/ari/en/index.html [accessed 10 February 2010].
  2. File TM. The epidemiology of respiratory tract infections. Semin Respir Infect. 2000;15:184–194
  3. Bartlett JG. Is activity against ‘atypical’ pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin Infect Dis. 2008;47(Suppl. 3):S232–S236
  4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl. 2):S27–S72
  5. Felmingham D, Grüneberg RN Alexander Project Group. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother. 2000;45:191–203
  6. Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother. 2002;50(Suppl. S1):49–59
  7. Jacobs MR. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Pediatr Infect Dis J. 2003;22(8 Suppl.):S109–S119
  8. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, et al. Emergence of multiply resistant pneumococci. N Engl J Med. 1978;299:735–740
  9. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831–1835
  10. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208–1213
  11. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–1746
  12. Farrell DJ, Morrissey I, Bakker S, Morris L, Buckridge S, Felmingham D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol. 2004;42:764–768
  13. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26:468–472
  14. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J. 2007;26:123–128
  15. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(Suppl. 3):16–20
  16. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009;15:1260–1264
  17. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917–1924
  18. Daneman N, McGeer A, Green K, Low DE Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis. 2006;43:432–438
  19. Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647)—the first ketolide. J Antimicrob Chemother. 2003;51:497–511
  20. Drugs RD. Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773. Drugs RD 2007; 8:95–102.
  21. Wierzbowski AK, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS). J Antimicrob Chemother. 2009;63:620–622
  22. Jones RN, Biedenbach DJ, Rhomberg PR, Fritsche TR, Sader HS. Antimicrobial characterization of CEM-101 activity against 331 respiratory tract pathogens including multidrug-resistant pneumococcal serogroup 19A (MDR-19A) isolates. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25–28 October 2008, Washington, DC. Washington, DC: ASM Press; 2008;[Abstract F1-3975]
  23. McGhee P, Nagai K, Appelbaum PC. Activity of CEM-101 compared to other agents against macrolide-susceptible and resistant streptococci. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25–28 October 2008, Washington, DC. Washington, DC: ASM Press; 2008;[Abstract F1-3974]
  24. Roblin PM, Kohlhoff SA, Hammerschlag MR. In vitro activity of CEM 101, a new ketolide antibiotic against Chlamydia trachomatis and Chlamydia pneumoniae. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25–28 October 2008, Washington, DC. Washington, DC: ASM Press; 2008;[Abstract F1-3978]
  25. Lemaire S, Van Bambeke F, Tulkens PM. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, towards Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother. 2009;53:3734–3743
  26. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother. 2009;53:2139–2141
  27. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2009.
  28. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
  29. Marco F, Biedenbach DJ, Jones RN. Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation. Diagn Microbiol Infect Dis. 1997;28:55–57
  30. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J. 2009;28:693–696
  31. Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis. 2009;9:384–392
  32. Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005–2006 U.S. faropenem surveillance study. Antimicrob Agents Chemother. 2007;51:4382–4389
  33. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34:482–492
  34. Champney WS, Mentens N, Zurawick K. An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004;49:239–247
  35. Farrell DJ, Shackcloth J, Barbadora KA, Green MD. Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations. Antimicrob Agents Chemother. 2006;50:817–818
  36. Santos JW, Nascimento DZ, Guerra VA, Rigo Vda S, Michel GT, Dalcin TC. Community-acquired staphylococcal pneumonia. J Bras Pneumol. 2008;34:683–689
  37. Jones R, Sader H, Biedenbach D. Antimicrobial characterization of CEM-101: activity against staphylococci, beta-haemolytic and viridians group streptococci. In: Abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 16–19 May 2009, Helsinki, Finland. Basel, Switzerland: ESCMID; 2009;

PII: S0924-8579(10)00075-0

doi: 10.1016/j.ijantimicag.2010.01.026

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 537-543 , June 2010

Article Tools

* Image Usage & Resolution